Discontinued — last reported Q3 '23
West Pharmaceutical Services Contract-Manufactured Products — Operating profit increased by 40.9% to $21.00M in Q3 2023 compared to the prior quarter. Year-over-year, this metric grew by 42.9%, from $14.70M to $21.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved margins or operational efficiency, while a decrease suggests rising costs or pricing pressure in the contract manufacturing market.
This metric measures the profitability of the Contract-Manufactured Products segment by subtracting operating expenses,...
Standard segment-level profitability metric used across all public companies to evaluate business unit performance.
wst_segment_contract_manufactured_products_operating_profit| Q2 '21 | Q3 '21 | Q2 '22 | Q3 '22 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|---|---|
| Value | $18.70M | $16.80M | $14.20M | $14.70M | $14.90M | $21.00M |
| QoQ Change | — | -10.2% | -15.5% | +3.5% | +1.4% | +40.9% |
| YoY Change | — | — | -24.1% | -12.5% | +4.9% | +42.9% |